C-reactive protein (CRP) is a biomarker of systemic inflammation that has been linked to accelerated decline in walking speed in older adults. The aim of the present study was to compare the CRP levels of PD patients with vs patients without freezing of gait (FOG). Patients and controls participating in the COPPADIS-2015 study that performed blood extraction for determining molecular serum biomarkers were included. Patients with FOG were identified as those with a score of 1 or greater on item-3 of the Freezing of Gait Questionnaire (FOG-Q). Immunoassay was used for determining ultrasensitive CRP (US-CRP) level (mg/dL). In the PD group (n = 225; 61.8 ± 9.5 years old, 61.8% males), 32% of the patients presented FOG but none in the control group (n = 65; 60.3 ± 6.1 years old, 56.9% males) (p < 0.0001). Differences in US-CRP level were significant in patients with FOG vs patients without FOG and vs controls (0.31 ± 0.52 vs 0.16 ± 0.21 vs 0.21 ± 0.22; p = 0.04). Significant differences were also observed between patients with vs without FOG (p = 0.001) but not between patients and controls (p = 0.163). US-CRP level was related to FOG (OR = 4.369; 95% CI 1.105–17.275; p = 0.036) along with H&Y (OR = 2.974; 95% CI 1.113–7.943; p = 0.030) and non-motor symptoms burden (NMSS total score; OR = 1.017; 95% CI 1.005–1.029; p = 0.006) after adjusting for age, gender, disease duration, equivalent daily levodopa dose, number of non-antiparkinsonian drugs per day, motor fluctuations, cognition, motor phenotype, and chronic use of anti-inflammatory drugs. The present study suggests that serum US-CRP level is related to FOG in PD patients. Inflammation could be linked to FOG development.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Beck depression inventory-II
Freezing of gait
Freezing of Gait Questionnaire
Non-motor Symptoms Scale
Parkinson’s Disease Cognitive Rating Scale
39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index
Parkinson’s Disease Sleep Scale
Postural instability gait difficulty
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale
Schwab & England Activities of Daily Living Scale
Unified Parkinson’s Disease Rating Scale
Visual Analog Fatigue Scale
- VAS Pain:
Visual analog scale pain
Amboni M, Stocchi F, Abbruzzese G, DEEP Study Group et al (2015) Prevalence and associated features of self-reported freezing of gait in Parkinson disease: the DEEP FOG study. Parkinsonism Relat Disord 21:644–649
Anand SS, Yusuf S (2010) C-reactive protein is a bystander of cardiovascular disease. Eur Heart J 31:2092–2096
Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ et al (2009) Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci 64:455–461
Bruunsgaard H (2005) Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol 78:819–835
Carvalho DZ, Schönwald SV, Schumacher-Schuh AF et al (2015) Overnight S100B in Parkinson’s disease: a glimpse into sleep-related neuroinflammation. Neurosci Lett 608:57–63
Cesari M, Penninx BW, Pahor M et al (2004) Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 59:242–248
Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R, Parkinson Study Group-DATATOP Investigators (2018) Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson’s disease. Mov Disord 33:762–770
de Farias CC, Maes M, Bonifacio KL et al (2016) Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett 617:66–71
Fasano A, Herman T, Tessitore A, Strafella AP, Bohnen NI (2015) Neuroimaging of freezing of gait. J Parkinsons Dis 5:241–254
Hassin-Baer S, Cohen OS, Vakil E et al (2011) Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson’s disease? J Neural Transm 118:539–543
Iansek R, Danoudis M (2016) Freezing of gait in Parkinson’s disease: its pathophysiology and pragmatic approaches to management. Mov Disord Clin Pract 4:290–297
Juma WM, Lira A, Marzuk A, Marzuk Z, Hakim AM, Thompson CS (2011) C-reactive protein expression in a rodent model of chronic cerebral hypoperfusion. Brain Res 1414:85–93
Kositsawat J, Barry LC, Kuchel GA (2013) C-reactive protein, vitamin D deficiency, and slow gait speed. J Am Geriatr Soc 61:1574–1579
Levin J, Bötzel K, Giese A, Vogeser M, Lorenzl S (2010) Elevated levels of methylmalonate and homocysteine in Parkinson’s disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord 29:553–559
Lindqvist D, Hall S, Surova Y et al (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease—associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189
Mancini M, Bloem BR, Horak FB et al (2019) Clinical and methodological challenges for assessing freezing of gait: future perspectives. Mov Disord (epub ahead of print)
Perez-Lloret S, Negre-Pages L, Damier P et al (2014) Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol 71:884–890
Perry VH (2004) The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 18:407–413
Qiu X, Xiao Y, Wu J, Gan L, Huang Y, Wang J (2019) C-reactive protein and risk of parkinson’s disease: a systematic review and meta-analysis. Front Neurol 10:384
Rees K, Stowe R, Patel S et al (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev 9:11
Sanjari Moghaddam H, Valitabar Z, Ashraf-Ganjouei A, Mojtahed Zadeh M, Ghazi Sherbaf F, Aarabi MH (2018) Cerebrospinal fluid C-reactive protein in Parkinson’s disease: associations with motor and non-motor symptoms. Neuromol Med 20:376–385
Santos García D, Jesús S, Aguilar M, Planellas LL, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Catalán MJ, López Díaz L, Puente V, García Moreno JM, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Menéndez González M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues-Boixar O, González Ardura J, Prieto Jurczynska C, Martinez-Martin P, Mir P; COPPADIS Study Group (2019) COPPADIS-2015 (COhort of Patient’s with PArkinson’s DIsease in Spain, 2015) An ongoing global Parkinson’s disease Project about disease progression with more than 1,000 subjects included. Results from the baseline evaluation. Eur J Neurol 66:151–158
Santos García D, Suárez Castro E, Expósito I et al (2017) Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and con-trol subjects. J Neurol Sci 373:210–215
Santos-García D, Mir P, Cubo E, COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015) et al (2016) a global–clinical evaluations, serum biomarkers, genetic studies and neuroimaging–prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol 16:26
Sathe K, Maetzler W, Lang JD et al (2012) S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain 135:3336–3347
Sawada H, Oeda T, Umemura A et al (2014) Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson’s disease: case-control study. PLoS One 9:e85886
Sawada H, Oeda T, Umemura A et al (2015) Baseline C-reactive protein levels and life prognosis in Parkinson disease. PLoS One 10:e0134118
Sousa AC, Zunzunegui MV, Li A, Phillips SP, Guralnik JM, Guerra RO (2016) Association between C-reactive protein and physical performance in older populations: results from the International Mobility in Aging Study (IMIAS). Age Ageing 45:274–280
Umemura A, Oeda T, Yamamoto K et al (2015) Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease. PLoS One 10:e0136722
van Kan Abellan G, Rolland Y, Andrieu S et al (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) task force. J Nutr Health Aging 13:881–889
Verghese J, Holtzer R, Lipton RB, Wang C (2012) High-sensitivity C-reactive protein and mobility disability in older adults. Age Ageing 41:541–545
Zhang H, Yin X, Ouyang Z et al (2016) A prospective study of freezing of gait with early Parkinson disease in Chinese patients. Medicine (Baltimore) 95:e4056
Collaborators (COPPADIS STUDY GROUP): Adarmes Astrid D, Almeria M, Alonso Losada MG, Alonso Cánovas A, Alonso Frech F, Álvarez Sauco M, Arnáiz S, Arribas S, Ascunce Vidondo A, Ávila MA, Bejr-Kasem H, Blázquez Estrada M, Botí M, Borrue C, Cabello González C, Cabo López I, Caballol N, Cámara Lorenzo A, Carrillo F, Casas E, Catalán MJ, Clavero P, Cortina Fernández A, Cubo E, Díez-Fairen M, Erro E, Estelrich Peyret E, Fernández Guillán N, Gámez P, Gallego M, García Caldentey J, García Campos C, García Moreno JM, Gastón I, Gómez Garre MP, González Aloy J, González Ardura J, González García B, González Palmás MJ, González Toledo GR, Golpe Díaz A, Grau Solá M, Guardia G, Horta-Barba A, Kulisevsky J, Kurtis M, Labandeira C, Labrador MA, Lacruz F, Lage Castro M, Legarda I, López Ariztegui N, López Díaz LM, López Manzanares L, López Seoane B, Macías Y, Mata M, Martí Andres G, Martí MJ, Martínez Castrillo JC, McAfee D, Meitín MT, Menéndez González M, Méndez del Barrio C, Miranda Santiago J, Morales Casado MI, Moreno Diéguez A, Nogueira V, Novo Amado A, Novo Ponte S, Ordás C, Pagonabarraga J, Pareés I, Pascual-Sedano B, Pérez Fuertes A, Pérez Noguera R, Planellas L, Prats MA, Prieto Jurczynska C, Redondo Rafales N, Rodríguez Méndez L, Rodríguez Pérez AB, Roldán F, Ruíz De Arcos M, Ruíz Martínez J, Sánchez Alonso P, Sánchez-Carpintero M, Sánchez Díez G, Sánchez Rodríguez A, Santacruz P, Segundo Rodríguez JC, Seijo M, Serarols A, Sierra Peña M, Tartari JP, Valero C, Vargas L, Vázquez Gómez R, Vela L, Villanueva C, Vives B, Villar MD.
Santos-García D. has received honoraria for educational presentations and/or advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. de Deus Fonticoba T. has received honoraria for educational presentations and advice service by Abbvie. Suárez Castro E: None. Aneiros Díaz A: None. Paz González JM. has received honoraria for educational presentations and/or advice service by UCB Pharma, Lundbeck, KRKA, and Zambon. Feal Panceiras MJ: None. García Sancho C: None. Jesús S. has received honoraria from Abbvie, Bial, Merz, UCB, and Zambon. She holds the competitive contract “Juan Rodés” supported by the Instituto de Salud Carlos III. Also, she has received grants from the Spanish Ministry of Economy and Competitiveness (PI18/01898) as well as the Consejería de Salud de la Junta de Andalucía (PI-0459-2018). Mir P. has received honoraria from Abbvie, Abbott, Allergan, Bial, Merz, UCB, and Zambon. He has received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación). He also received grants from Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, and the Fundación Mutua Madrileña. Aguilar M: UCB and Schwabe with assistance to a Congress; Nutricia with assistance to a Congress and payment of lecture. Pastor P: None. Hernández Vara J: has received travel bursaries and educational grants from Abbvie and has received honoraria for educational presentations from Abbvie, Teva, Bial, Zambon, Italfarmaco, and Sanofi-Genzyme. de Fábregues-Boixar O. has received honoraria for educational presentations and advice service by Bial, Zambon, Abbvie, KRKA, and Teva. Puente V. has served as consultant for Abbvie and Zambon; has received grant/research from Abbvie. Crespo Cuevas A: None. González-Aramburu I: None. Infante J. has received travel bursaries and honoraria for educational presentations from Abbvie and Zambon. Carrillo Padilla F. has received honoraria from Zambon (SEN Congress assistance). Pueyo M. has received honoraria from Zambon for educational presentations and SEN Congress assistance and of Medtronic for course assistance. Escalante S. has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. Bernardo N: None. Solano B. has received honoraria for educational presentations and advice service by UCB, Zambon, Teva, Abbvie, and Bial. Cots Foraster A has received honoraria for educational presentations by UCB and Zambon, Has received financial help to Master courses (Master en Trastornos del Movimiento, Ed Viguera, 2017–2018) from UCB an Zambon. Martinez-Martin P: Honoraria: from Editorial Viguera for lecturing in courses; International Parkinson and Movement Disorder Society for management of the Program on Rating Scales; Air Liquide, Abbvie, and HM Hospitales de Madrid for advice in clinic-epidemiological studies. License fee payments for the King’s Parkinson’s Disease Pain scale.
Conflicts of interest
All authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Santos-García, D., de Deus Fonticoba, T., Suárez Castro, E. et al. High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients. J Neural Transm 126, 1599–1608 (2019). https://doi.org/10.1007/s00702-019-02096-8
- C-Reactive protein
- Parkinson’s disease